MedTrace Logo

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

NCT07050433 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 48

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-201 in order to participate in this study. The purpose of this companion study is to learn more about biomarkers, particularly a biomarker called CXCR2, and investigate if CXCR2 can predict who will receive benefit from the SYNERGY-201 drug combination. This study will also investigate how CXCR2 and other biomarkers change over time when participants receive the SYNERGY-201 drug combination. CXCR2 is of particular interest because the SYNERGY-201 drug, SX-682, inhibits CXCR2. After participants provide consent, blood samples will be collected for research purposes at three SYNERGY-201 visits (Baseline, Cycle 3 Day 1 and End of Study Drug). Up to 20 participants will also receive tumor biopsies at the Baseline and SYNERGY-201 Cycle 3 Day 1 visits. Clinical and study data collected as part of SYNERGY-201 will also be used for this study.

Conditions

Interventions

DIAGNOSTIC_TEST

CXCR2 as a biomarker

CXCR2 biomarker expression will be measured in tumor and immune cell samples

Sponsors & Collaborators

Principal Investigators

  • Andrew Armstrong, MD · Duke University

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-07
Primary Completion
2027-07-01
Completion
2028-01-01
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07050433 on ClinicalTrials.gov